//
Readmission and Mortality After Hospitalization for Myocardial Infarction and Heart Failure
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF
Angiotensin–neprilysin inhibition versus enalapril in heart failure
The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment
Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors